Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Skeletal Effects of Inducible ERα Deletion in Osteocytes in Adult Mice
Doolittle, Madison L. , Saul, Dominik , Kaur, Japneet , Rowsey, Jennifer L. , Eckhardt, Brittany, Vos, Stephanie J. B. , Grain, Sarah, Kroupova, Kveta, Ruan, Ming, Weivoda, Megan , Oursler, Merry Jo, Vos, Stephanie, Farr, Joshua N , Monroe, David G , Khosla, Sundeep , Saul, Dominik , Vos, Stephanie, Farr, Joshua N. , Monroe, David G. , Khosla, Sundeep

Mayo Clinic

Journal of Bone and Mineral Research | July 5, 2022 | Volume: 37 | Issue: 9 | Pages: 1750-1760

10.1002/jbmr.4644 | PMID 35789113 Get It

ABSTRACT Estrogen is known to regulate bone metabolism in both women and men, but substantial gaps remain in our knowledge of estrogen and estrogen receptor alpha (ERα) regulation of adult bone metabolism. Studies using global ERα-knockout mice were confounded by high circulating sex-steroid levels, and osteocyte/osteoblast-specific ERα deletion may be confounded by ERα effects on growth versus the adult skeleton. Thus, we developed mice expressing the tamoxifen-inducible CreERT2 in osteocytes using the 8-kilobase (kb) Dmp1 promoter (Dmp1CreERT2). These mice were crossed with ERαfl//fl mice to create ERαΔOcy mice, permitting inducible osteocyte-specific ERα deletion in adulthood. After intermittent tamoxifen treatment of adult 4-month-old mice for 1 month, female, but not male, ERαΔOcy mice exhibited reduced spine bone volume fraction (BV/TV (−20.1%, p = 0.004) accompanied by decreased trabecular bone formation rate (−18.9%, p = 0.0496) and serum P1NP levels (−38.9%, p = 0.014). Periosteal (+65.6%, p = 0.004) and endocortical (+64.1%, p = 0.003) expansion were higher in ERαΔOcy mice compared to control (Dmp1CreERT2) mice at the tibial diaphysis, reflecting the known effects of estrogen to inhibit periosteal apposition and promote endocortical formation. Increases in Sost (2.1-fold, p = 0.001) messenger RNA (mRNA) levels were observed in trabecular bone at the spine in ERαΔOcy mice, consistent with previous reports that estrogen deficiency is associated with increased circulating sclerostin as well as bone SOST mRNA levels in humans. Further, the biological consequences of increased Sost expression were reflected in significant overall downregulation in panels of osteoblast and Wnt target genes in osteocyte-enriched bones from ERαΔOcy mice. These findings thus establish that osteocytic ERα is critical for estrogen action in female, but not male, adult bone metabolism. Moreover, the reduction in bone formation accompanied by increased Sost, decreased osteoblast, and decreased Wnt target gene expression in ERαΔOcy mice provides a direct link in vivo between ERα and Wnt signaling. © 2022 American Society for Bone and Mineral Research (ASBMR).
Exercise Counters the Age-Related Accumulation of Senescent Cells
Zhang, Xu , Englund, Davis A. , Aversa, Zaira, Jachim, Sarah K. , White, Thomas A. , Zhang, Xu , LeBrasseur, Nathan K. , Englund, Davis A.

Mayo Clinic

Exercise and Sport Sciences Reviews | July 1, 2022 | Volume: 50 | Issue: 4 | Pages: 213-221

10.1249/jes.0000000000000302 | PMID 35776782 Get It

We propose the beneficial effects of exercise are in part mediated through the prevention and elimination of senescent cells. Exercise counters multiple forms of age-related molecular damage that initiate the senescence program and activates immune cells responsible for senescent cell clearance. Preclinical and clinical evidence for exercise as a senescence-targeting therapy and areas needing further investigation are discussed.
Pralsetinib in patients (pts) with advanced or metastatic RET-altered thyroid cancer (TC): Updated data from the ARROW trial.
Zhu, Viola W. , Brose, Marcia S. , Wirth, Lori J. , Adkins, Douglas, Godbert, Yann , Ahn, Myung‐Ju , Lin, Chia‐Chi , Zhang, Hui , Zalutskaya, Alena , Barata, Teresa, Scalori, Astrid, Mansfield, Aaron S. , Subbiah, Vivek , Schüler, Martin , Hadoux, Julien , Curigliano, Giuseppe , Garralda, Elena , Adkins, Douglas, Cassier, Philippe A. , Cho, Byoung Chul , Zalutskaya, Alena A. , Taylor, Matthew H.

Mayo Clinic

Journal of Clinical Oncology | June 29, 2022 | Volume: 40 | Issue: 16_suppl | Pages: 6080-6080

10.1200/jco.2022.40.16_suppl.6080 Get It

6080 Background: Alterations in RET are targetable oncogenic drivers in TC. Pralsetinib is a highly potent, selective RET inhibitor, with demonstrated efficacy in pts with RET-altered TC. In a previous analysis of the Phase I/II ARROW trial (NCT03037385; data cutoff: 22 May 2020), overall response rates [ORR; measurable-disease population] with pralsetinib at 400 mg once daily (QD) were 60% (33/55) and 71% (15/21) in pts with RET-mutant medullary TC ( RET-mutant MTC) who had received prior multikinase inhibitors cabozantinib and/or vandetanib (C/V), and those who were treatment naïve, respectively, and 89% (8/9) in pts with previously treated RET fusion-positive TC ( RET-fp TC). Here we report an updated analysis of these cohorts in the intention-to-treat (ITT) population. Methods: Adult pts with RET-altered locally advanced/metastatic TC who had enrolled in ARROW and initiated pralsetinib at 400 mg QD, were included. Phase II primary endpoints: ORR (by blinded independent central review, per RECIST v1.1) and safety. Efficacy endpoints for this analysis were assessed in the ITT population. Safety was assessed in all pts with RET-altered TC who initiated pralsetinib at 400 mg QD. Enrolment cutoff: 23 August 2020 for the ITT population; data cutoff: 12 April 2021. Results: The ITT population comprised 145 pts with RET-mutant MTC (with or without prior systemic therapy, including C/V) and 22 pts with RET-fp TC, 21 of whom had received prior systemic therapy (including multikinase inhibitor[s] and/or radioactive iodine). In pts with RET-mutant MTC who had received prior C/V (n = 67), ORR was 51% (34/67; 95% CI 38–63; 2 complete responses [CR]; 32 partial responses [PR]), median duration of response (DoR) was 25.8 months (95% CI 18.0–not reached [NR]) and median progression-free survival (PFS) was 24.9 months (95% CI 19.7–31.2). In treatment-naïve pts with RET-mutant MTC, ORR was 72% (48/67; 95% CI 59–82; 4 CR; 44 PR), and median DoR and median PFS were not reached. In pts with previously treated RET-fp TC, ORR was 86% (18/21; 95% CI 64–97; 3 CR; 15 PR), median DoR was 17.5 months (95% CI 16.0–NR) and median PFS was 19.4 months (95% CI 13.0–NR). Median overall survival (OS) was not reached in any of the cohorts. The safety population comprised 172 pts with RET-altered TC treated at 400 mg QD. The most common treatment-related adverse events (TRAEs) were increased aspartate aminotransferase (n = 67; 39%), anemia (n = 60; 35%), hypertension (n = 57; 33%) and decreased white blood cell count (n = 52; 30%). Serious TRAEs were reported in 27 pts (16%); the most frequent was pneumonitis (n = 5; 3%). Nine pts (5%) discontinued pralsetinib due to a TRAE and one patient ( < 1%) died due to a TRAE ( pneumocystis jirovecii pneumonia) following 44 days ( < 3 cycles) on pralsetinib. Conclusions: In this updated analysis including more pts, pralsetinib continues to be efficacious with a manageable safety profile in pts with RET-altered TC. Clinical trial information: NCT03037385.
Plasma glial fibrillary acidic protein in autosomal dominant Alzheimer’s disease: associations with β-amyloid-PET, neurodegeneration and cognition
Chatterjee, Pratishtha , Gordon, Brian A. , Boonkamp, Lynn , Armstrong, Nicola J. , Xiong, Chengjie , Li, Yan , Taddei, Kevin , Chhatwal, Jasmeer P. , Graff‐Radford, Neill R. , Farlow, Martin R. , Mori, Hiroshi , Perrin, Richard J. , Fagan, Anne M. , Gordon, Brian A , Vermunt, Lisa , Pedrini, Steve , Singh, Abhay Kumar , Sohrabi, Hamid R. , Molloy, Mark P. , Benzinger, Tammie L.S. , Morris, John C. , Karch, Celeste M. , Berman, Sarah , Day, Gregory S. , Fox, Nick C. , Goate, Alison , Hassenstab, Jason , Lee, Jae‐Hong , Xiong, Chengjie , McDade, Eric , Sánchez‐Valle, Raquel , Schofield, Peter R. , Jucker, Mathias , Masters, Colin L. , Bateman, Randall J. , Martins, Ralph N. , Teunissen, Charlotte E.

Mayo Clinic

No container title available | June 29, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1752559/v1 Get It

Abstract Glial fibrillary acidic protein (GFAP) is a promising candidate blood-based biomarker for Alzheimer’s disease (AD) diagnosis and prognostication. The timing of its disease-associated changes, its clinical correlates, and biofluid-type dependency will influence its clinical utility. We evaluated plasma, serum, and CSF GFAP in families with autosomal dominant AD (ADAD), leveraging the predictable age at symptom onset to determine changes by stage of disease. Plasma GFAP elevations appear a decade before expected symptom onset, after β-amyloid accumulation and prior to neurodegeneration and cognitive decline. Plasma GFAP distinguished β-amyloid-positive from β-amyloid-negative ADAD participants and showed a stronger relationship with β-amyloid load in asymptomatic than symptomatic ADAD. Higher plasma GFAP was associated with the degree and rate of neurodegeneration and cognitive impairment. Serum GFAP showed similar relationships, but these were less pronounced for CSF GFAP. Our findings support a role for plasma GFAP as a clinical biomarker for β-amyloid-associated cognitive deterioration in AD.
Incidence and management of pleural effusions in patients with Wilms tumor: A Pediatric Surgical Oncology Research Collaborative study
Al‐Hadidi, Ameer , Rinehardt, Hannah , Sutthatarn, Pattamon , Condon, Sienna, Chen, Stephanie , Wong‐Michalak, Shannon , Short, Scott S. , Meyers, Rebecka L. , Johnston, Michael E. , Zens, Tiffany , Dasgupta, Roshni , Calabro, Kristen , Piché, Nelson , Callas, Hannah, McKay, Katlyn G. , Lovvorn, Harold N. , Tracy, Elisabeth T. , Lund, Sarah , Polites, Stephanie F. , Davidson, Jacob , Dhooma, Janel, Seemann, Natashia M. , Marquart, John , Gainer, Haley , Lal, Dave R. , Rich, Barrie S. , Glick, Richard D. , Maloney, Lauren , Radu, Stephani, Fialkowski, Elizabeth , Kwok, Pei En , Romao, Rodrigo , Newman, Erika A. , Diehl, Thomas M. , Polcz, Valerie E., Petroze, Robin T. , Aldrink, Jennifer H. , Lautz, Timothy , Lund, Sarah B, Tracy, Elisabeth T , Aldrink, Jennifer H , Dasgupta, Roshni , Talbot, Lindsay J , Murphy, Andrew J. , Whitlock, Richard S. , Naik‐Mathuria, Bindi , Utria, Alan Fremder , Rothstein, David H. , Kim, Eugene S. , Kastenberg, Zachary J. , Malek, Marcus M. , Lautz, Timothy B. , Commander, Sarah Jane , Radu, Stephanie , Rubalcava, Nathan S. , Ehrlich, Peter F. , Le, Hau D. , Stanek, Joseph

Mayo Clinic

International Journal of Cancer | June 24, 2022 | Volume: 151 | Issue: 10 | Pages: 1696-1702

10.1002/ijc.34188 | PMID 35748343 Get It

AbstractWilms tumor (WT) is the most common renal malignancy in children. Children with favorable histology WT achieve survival rates of over 90%. Twelve percent of patients present with metastatic disease, most commonly to the lungs. The presence of a pleural effusion at the time of diagnosis of WT may be noted on staging imaging; however, minimal data exist regarding the significance and prognostic importance of this finding. The objectives of our study are to identify the incidence of pleural effusions in patients with WT, and to determine the potential impact on oncologic outcomes. A multi‐institutional retrospective review was performed from January 2009 to December 2019, including children with WT and a pleural effusion on diagnostic imaging treated at Pediatric Surgical Oncology Research Collaborative (PSORC) participating institutions. Of 1259 children with a new WT diagnosis, 94 (7.5%) had a pleural effusion. Patients with a pleural effusion were older than those without (median 4.3 vs 3.5 years; P = .004), and advanced stages were more common (local stage III 85.9% vs 51.9%; P < .0001). Only 14 patients underwent a thoracentesis for fluid evaluation; 3 had cytopathologic evidence of malignant cells. Event‐free and overall survival of all children with WT and pleural effusions was 86.2% and 91.5%, respectively. The rate and significance of malignant cells present in pleural fluid is unknown due to low incidence of cytopathologic analysis in our cohort; therefore, the presence of an effusion does not appear to necessitate a change in therapy. Excellent survival can be expected with current stage‐specific treatment regimens.
Exuberant late gadolinium enhancement in hypertrophic cardiomyopathy as a precursor to ‘burn out’
Gweun, John , Thomas, Sarah , Geske, Jeffrey B. , Geske, Jeffrey B , Thomas, Sarah C

Mayo Clinic

European Heart Journal - Case Reports | June 24, 2022 | Volume: 6 | Issue: 6 | Pages: No page available

10.1093/ehjcr/ytac243 | PMID 35775015 Get It

P961: CILTACABTAGENE AUTOLEUCEL, A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: 2-YEAR POST LPI RESULTS FROM THE PHASE 1B/2 CARTITUDE-1 STUDY
Lin, Yaxiong, Martin, Thomas , Berdeja, J. G., Deol, Abhinav , Htut, Myo, Munshi, Nikhil C. , O’Donnell, Elisabeth K., Jackson, C. C., Yeh, Tzu‐Min, Banerjee, Arnob , Zudaire, Enrique, Pacaud, Lida , Usmani, S. Z., Jakubowiak, Andrzej , Agha, Mounzer , Cohen, Adam D. , Htut, Myo , Lesokhin, Alexander M. , Jackson, C.C., Madduri, Deepu , Zhou, C., Jagannath, Sundar

Mayo Clinic

HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 851-852

10.1097/01.hs9.0000846712.74284.0f Get It

P971: ADJUSTED COMPARISON OF PATIENT REPORTED OUTCOMES FROM CARTITUDE-1 AND LOCOMMOTION COMPARING CILTACABTAGENE AUTOLEUCEL VERSUS REAL WORLD CLINICAL PRACTICE IN TRIPLE-CLASS EXPOSED MULTIPLE MYELOMA
Weisel, K., Mateos, María‐Victoria , Martin, Thomas , Berdeja, J. G., Lin, Yi , Thilakarathne, Pushpike, Diels, Joris , Haefliger, B., Hague, Clare, Gonzalez, A., Schecter, Jordan M. , Gries, Katharine S. , Strulev, Vadim, Nesheiwat, Tonia, Pacaud, Lida , Einsele, H., Moreau, P., Vincent, Laure , Jakubowiak, Andrzej , Jagannath, Sundar , Ghilotti, Francesca , Moreau, P.

Mayo Clinic

HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 861-862

10.1097/01.hs9.0000846752.50612.48 Get It

Successful use of telemedicine for evaluation of infantile hemangiomas during the early COVID‐19 pandemic: A cross‐sectional study
Kittler, Nicole W. , Frieden, Ilona J. , Siegel, Dawn H. , Horii, Kimberly A., Mathes, Erin F., Blei, Francine , Haggstrom, Anita N. , Streicher, Jenna L., Metry, Denise W. , Garzón, Maria C. , Morel, Kimberly D. , Lauren, Christine T. , Baselga, Eulàlia , Tollefson, Megha M. , Newell, Brandon , McCuaïg, Catherine , Chamlin, Sarah L. , Becker, Emily M. , Cossio, M , Shah, Sonal D. , Metry, Denise W , Fernandez Faith, Esteban , Baselga, Eulalia , Cossio, Maria L , Shah, Sonal D , Abuabara, Katrina , Hogeling, Marcia , Faith, Esteban Fernández , Mancini, Anthony J.

Mayo Clinic

Pediatric Dermatology | June 23, 2022 | Volume: 39 | Issue: 5 | Pages: 718-726

10.1111/pde.15040 | PMID 35734850 Get It

AbstractBackground/ObjectivesThe COVID‐19 pandemic prompted a rapid expansion in the use of telemedicine. This study aimed to assess the experiences of hemangioma specialists utilizing telemedicine during the COVID‐19 pandemic to evaluate and manage infantile hemangiomas (IH), including perceived effectiveness of different modalities and barriers to care delivery.MethodsMulticenter cross‐sectional study asking providers to describe their experiences using telemedicine for initial evaluation of IH from March to September 2020.ResultsThe study included 281 patients from 15 medical centers internationally. Median time from referral to evaluation was 17 days. Median physician confidence in performing evaluations via telemedicine was 95.0 (IQR 90.0–100.0). Most evaluations were performed via video communication with photographs or audio communication with photographs; when not initially available, photographs were requested in 51.4%. Providers preferred follow‐up modalities that included photographs.ConclusionsPhysicians with extensive expertise in managing IH are confident in their abilities to assess and manage IH via telemedicine including initiating treatment in patients without risk factors for beta‐blocker therapy. There was a preference for hybrid modalities that included photographs. The data suggest that telemedicine can be effective for managing IH and may decrease wait times and improve specialist reach to underserved areas.